Related Experiment Video
Updated: May 10, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers
Tadeja Rezen1, Viola Tamasi, Anita Lövgren-Sandblom
1Center for Functional Genomics and Bio-Chips, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia. tadeja.rezen@mf.uni-lj.si
Background:
Detoxification in the liver involves activation of nuclear receptors, such as the constitutive androstane receptor (CAR), which regulate downstream genes of xenobiotic metabolism. Frequently, the metabolism of endobiotics is also modulated, resulting in potentially harmful effects. We therefore used 1,4-Bis [2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP) to study the effect of CAR activation on mouse hepatic transcriptome and lipid metabolome under conditions of diet-induced hyperlipidemia.
Results:
Using gene expression profiling with a dedicated microarray, we show that xenobiotic metabolism, PPARalpha and adipocytokine signaling, and steroid synthesis are the pathways most affected by TCPOBOP in normal and hyperlipidemic mice. TCPOBOP-induced CAR activation prevented the increased hepatic and serum cholesterol caused by feeding mice a diet containing 1% cholesterol. We show that this is due to increased bile acid metabolism and up-regulated removal of LDL, even though TCPOBOP increased cholesterol synthesis under conditions of hyperlipidemia. Up-regulation of cholesterol synthesis was not accompanied by an increase in mature SREBP2 protein. As determined by studies in CAR -/- mice, up-regulation of cholesterol synthesis is however CAR-dependent; and no obvious CAR binding sites were detected in promoters of cholesterogenic genes. TCPOBOP also affected serum glucose and triglyceride levels and other metabolic processes in the liver, irrespective of the diet.
Conclusion:
Our data show that CAR activation modulates hepatic metabolism by lowering cholesterol and glucose levels, through effects on PPARalpha and adiponectin signaling pathways, and by compromising liver adaptations to hyperlipidemia.
Insights
Constitutive androstane receptor (CAR) activation by TCPOBOP impacts liver metabolism. CAR activation lowers cholesterol and glucose levels, affecting pathways like PPARalpha and adiponectin signaling, despite compromising hyperlipidemia adaptations.
Area of Science:
- Hepatology
- Molecular Toxicology
- Metabolomics
Background:
- Liver detoxification relies on nuclear receptors like constitutive androstane receptor (CAR) to regulate xenobiotic metabolism.
- CAR activation can unintentionally alter endobiotic metabolism, potentially causing adverse effects.
- The study investigates CAR activation's impact on liver transcriptome and lipid metabolism in diet-induced hyperlipidemia using TCPOBOP.
Purpose of the Study:
- To investigate the effects of CAR activation on the mouse hepatic transcriptome and lipid metabolome.
- To understand how CAR activation influences metabolic pathways, particularly in the context of hyperlipidemia.
- To elucidate the role of CAR in regulating cholesterol, glucose, and triglyceride levels.
Main Methods:
- Gene expression profiling using a dedicated microarray to analyze hepatic transcriptome changes.
- Metabolomic analysis to assess lipid profiles in normal and hyperlipidemic mice.
- Utilizing CAR knockout (CAR-/-) mice to confirm CAR-dependent effects.
Main Results:
- TCPOBOP-activated CAR significantly affected xenobiotic metabolism, PPARalpha and adipocytokine signaling, and steroid synthesis pathways.
- CAR activation prevented diet-induced increases in hepatic and serum cholesterol by enhancing bile acid metabolism and LDL removal.
- Despite increased cholesterol synthesis, CAR activation lowered serum glucose and triglyceride levels, independent of diet.
Conclusions:
- CAR activation broadly modulates hepatic metabolism, reducing cholesterol and glucose levels.
- These metabolic changes are mediated through effects on PPARalpha and adiponectin signaling pathways.
- CAR activation compromises the liver's adaptive responses to hyperlipidemia.

